NL-OMON48971
Completed
Not Applicable
SURVive: investigating new imaging criteria for non-operative treatment following neoadjuvant chemoradiation in rectal cancer patients - Novel imaging criteria after neoadjuvant therapy rectal cancer.
Heelkunde0 sites20 target enrollmentStarted: TBDLast updated:
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Heelkunde
- Enrollment
- 20
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational invasive
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Patients with rectal cancer who are eligible for treatment with neoadjuvant
- •chemoradiation
- •Patients treated in the LUMC, HMC, Alrijne or GHZ.
- •Age 18 years and older;
- •Willing to participate in all aspects of the study
Exclusion Criteria
- •Patients with rectal cancer, receiving chemoradiation as part of the TESAR
- •Diabetes mellitus
- •Claustrofobia (low dose benzodiazepines are allowed);
- •Prior radiotherapy to the pelvis
- •If female and fertile: signs and symptoms of pregnancy or a positive pregnancy
- •test / breast\-feeding (a formal negative pregnancy test is not obligatory);
- •Presence of any psychological, familial, sociological or geographical condition
- •potentially hampering compliance with the study protocol and follow\-up schedule
- •Contraindications for Magnetic Resonance Imaging
- •Patient has evidence of infection in the 14 days prior to the FDG\-PET/CT scan
Investigators
Similar Trials
Completed
Not Applicable
Investigating new imaging criteria for non-operative treatment following neoadjuvant chemoradiation in rectal cancer patientsNL-OMON22673eiden Unversity Medical Center20
Active, not recruiting
Phase 1
Amyloid imaging in Alzheimer’s disease, frontotemporal dementia and healthy volunteersse of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.MedDRA version: 14.0 Level: PT Classification code 10061816 Term: Diagnostic procedure System Organ Class: 10022891 - InvestigationsEUCTR2008-003597-18-GBAvid Radiopharmaceuticals, Inc34
Completed
Phase 2
Amyloid imaging in Alzheimer's disease, frontotemporal dementia and healthy volunteersFrontotemporal dementia and Alzheimer's diseaseNervous System DiseasesAlzheimer's diseaseISRCTN58435532Avid Radiopharmaceuticals Inc.40
Recruiting
Not Applicable
Exploring new imaging opportunities using a large axial field of view PET-CT systemcancer10027656NL-OMON51671Amsterdam UMC48
Active, not recruiting
Phase 1
Evaluation of the evolution of imaging markers (using Magnetic Resonnance Imaging) of cartilage degradation in patients with knee osteoarthritis receiving DROGLICAN®: a Pilot StudyKnee OsteoarthritisTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2015-005681-37-BEBIOIBERICA S.A.20